

**STUDY OF CARDIAC AFFECTION
IN END STAGE-RENAL FAILURE BY
ECHOCARDIOGRAPHY.**


Thesis Submitted for Partial Fulfillment of M.P. Degree in

*Cardiology
Presented by:*

Dr. Kameil Danial Zatton
M.B., B.Ch.

Supervisors:

**Professor Dr.
ALI RAMZY**
Professor of Cardiology
Faculty of Medicine - Ain Shams University
Vice President of Ain Shams University



Dr. Mona Abu El Saud
Lecturer of Cardiology
Faculty of Medicine - Ain Shams University

Dr. Gamal Abu El Nasr
M.D. Cardiology
N.H.I., Embaba.

**Faculty of Medicine
Ain Shams University**

1993



بِسْمِ اللَّهِ الْقَوِي



ACKNOWLEDGMENT

First, all thanks must go to our God, who helped us in achievement of this work.

I would like to express my sincere appreciation and thanks to Prof. Dr. Ali Ramzy, Professor of Cardiology, Ain Shams University, for accepting the supervision of this work and for his unvaluable assistance and faithful guidance. I am really indebted for his patience and kindness.

My deepest thanks also go for Dr. Mona Abu El Saud, Lecturer of Cardiology, Ain Shams University, whose help, advice and encouragement were essential for achievement of this thesis.

I would like to express my heart felt thanks to Dr. Gamal Abu El Nasr, M.D. Cardiology N.H.I., Embaba., who shared with his heart in achievement of this work.

KAMEIL DANIAL

1993

CONTENTS

	<i>Page</i>
Review of Literature	
I. Chronic Renal Failure	1
II. Cardiovascular Complications of Chronic Renal Failure and Hemodialysis.....	5
 Chapter I:	
Pericarditis	
1. <i>Introduction</i>	5
2. <i>Incidence</i>	5
3. <i>Pathology</i>	6
4. <i>Etiology and Pathogenesis</i>	7
5. <i>Clinical Pictures</i>	14
6. <i>Complications</i>	16
7. <i>Investigations</i>	19
8. <i>Treatment</i>	25
 Chapter 2:	
Heart Failure	
1. <i>Introduction</i>	28
2. <i>Incidence</i>	28
3. <i>Risk factors</i>	28
4. <i>Investigations</i>	40
5. <i>Management</i>	47
 Chapter 3:	
Hypertension	
1. <i>Introduction</i>	50
2. <i>Incidence</i>	50
3. <i>Pathogenesis</i>	50
4. <i>Management</i>	57
 Chapter 4:	
Ischemic Heart Disease	
1. <i>Incidence</i>	62
2. <i>Risk factors</i>	63
3. <i>Role of echocardiography in ischemic heart disease</i>	70
4. <i>Management</i>	72

Chapter 5:	
Arrhythmias	
1. <i>Introduction and Incidence</i>	75
2. <i>Arrhythmogenic factors</i>	76
3. <i>Long term therapy of arrhythmias in patients on hemodialysis</i>	81
Chapter 6:	
Infective Endocarditis	
1. <i>Incidence</i>	83
2. <i>Etiology</i>	83
3. <i>Predisposing factors</i>	83
4. <i>Clinical pictures</i>	84
5. <i>Investigations</i>	85
6. <i>Management</i>	86
Chapter 7:	
Valvular affection in chronic renal failure with long-term hemodialysis	
1. <i>Incidence</i>	88
2. <i>Risk factors</i>	90
3. <i>Role of echocardiography in diagnosis of valvular heart disease</i>	93
4. <i>Clinical versus Doppler echocardiographic diagnosis of valvular affection in dialysis patients</i>	95
Subjects and Methods	96
Results	102
Discussion	144
Conclusion	157
Summary	158
References	159
Arabic Summary	

List of Figures

Figure No:	Page
1. Prevalence of abnormal clinical findings in 20 patients on long term hemodialysis.	104
2. ECG of patient No 20 showing sinus rhythm, raising ST-segment consistent with pericarditis.	105
3. Plain chest x-ray postero-anterior view showing increased C/T ratio, hilar congestion, straightening of left cardiac border in patient No 11.	107
4. Correlation between left ventricular mass index (LVMI) and left atrial (LA) diameter in patients group.	115
5. Correlation between hemoglobin (Hb) concentration and left ventricular end diastolic diameter (LVEDD) in patients group.	115
6. M-mode echocardiography showing left ventricular hypertrophy with dilatation and hypocontractility (FS=13%) in patient No 3. ...	116
7. M-mode echocardiography showing concentric left ventricular hypertrophy with good systolic function (FS=31%) with evidence of pericardial effusion and thickening in patient No 12.	116
8. Correlation between systolic blood pressure (SBP) and left ventricular muscle mass index (LVMI) in patients group.	117
9. Correlation between diastolic blood pressure (DBP) and left ventricular muscle mass index (LVMI) in patients group.	117
10. Correlation between left ventricular end systolic wall stress (ESS) and fractional shortening percent (FS%) in patients group.	118
11. Correlation between left ventricular end systolic wall stress (ESS) and ejection fraction percent (EF%) in patients group.	118
12. Mitral Doppler flow showing only visible presystolic A waves with evidence of mitral regurgitation in patient No 12.	119
13. Correlation between peak velocity of early left ventricular filling (E) in patients without mitral regurgitation (MR) and their systolic blood pressure (SBP).	119
14. Mitral Doppler flow showing impaired left ventricular filling in patient No 6.	120
15. Correlation between peak velocity of early left ventricular (LV) filling (E) and isovolumic relaxation (IVR) time in patients group (except cases No 4, 12, and 16).	120
16. Correlation between ratios of peak velocity of early left ventricular filling to peak velocity of late left ventricular filling (E/A ratios) and isovolumic relaxation (IVR) time in patients group (except cases No 4, 12, and 16).	121

17. Prevalence of abnormal echocardiographic findings in 20 patients on long term hemodialysis.	122
18. Mitral Doppler flow showing evidence of moderate mitral regurgitation in patient No 11.	123
19. Two-dimensional echocardiography apical 5 chambers view showing thickened sclerosed aortic valve leaflets in patient No 18.	123
20. Two-dimensional echocardiography 4 chambers view showing localized pericardial effusion with thickened pericardium near left ventricular apex in patient No 7.	124
21. M-mode echocardiography showing pericardial effusion and thickening behind left ventricular posterior wall in patient No 7.	124
22. Two-dimensional echocardiography 4 chambers view at end diastole showing GSA of myocardium in patient No 9.	125

List of Tables

Table No	Page
1. Echo cardiographic findings in 20 patients on maintenance hemodialysis.	114
2. Demographic and clinical data of dialysis patients and control groups (mean $\pm$ SD, and P values).	132
3. Biochemical data of patients and control (mean $\pm$ SD, P values, and significance).	132
4. Echocardiographic parameters of patients and control (mean $\pm$ SD, P values, and significane).	136
5. Doppler parameters of left ventricular diastolic filling of both patients and control (mean $\pm$ SD, P values, and significance).	137
- Individual data of patients group.	138
- Individual data of control group.	141

Errata

Wrong	Correct	page
Prevalemce	Prevalence	List of figures
patiens	patients	List of figures
were	where	23
hyperphostatemia	hyperphosphatemia	34
chromic	chronic	50
oftern	often	52
examinatin	examination	97
early	early	100
antimflamatory	anti-inflammatory	103
pateints	patients	106
clacium	calcium	108
diamter	diameter	115
<0.05	>0.05	136
pateints	patients	145
respectivley	respectively	146
atruim	atrium	149

REVIEW OF LITERATURE

"I"
CHRONIC RENAL
FAILURE

CHRONIC RENAL FAILURE

Definitions

Acute renal failure is a syndrome characterized by a relatively rapid decline in renal function that leads to the accumulation of water, crystalloid solutes, and nitrogenous metabolites in the body (**Grantham, 1988**), while chronic renal failure is a progressive and generally irreversible decline in glomerular filtration rate (**Kokko, 1988**). On the other hand, uremia is a serious toxic condition that occurs as a terminal stage in both acute and chronic renal failure, it begins when renal function approaches 5 percent of normal. Uremia is often end by coma followed shortly by death (**Schreiner, 1989**).

Stages of Progressive Renal Failure

The stages, in order of progression, are 1-reduced renal reserve, 2-renal insufficiency, 3-renal failure, 4-uremic syndrome, and 5-endstage renal disease (ESRD) (**Zollo, 1991**).

Patients with normal renal function have nephron mass in excess of that necessary to maintain a normal glomerular filtration rate, therefore, with progressive loss of renal mass, renal reserve is lost initially which is not reflected by a rise of blood urea nitrogen (BUN), and creatinine or in a disturbance of

homeostasis. On the other hand, if the progression continues, this stage is followed by renal insufficiency, which is associated with mild elevation of BUN, and creatinine and very mild symptoms, including nocturia and easy fatigability. However, with further progression, renal failure ensues, this stage is characterized by apparent abnormalities of renal excretory function, including disturbances in water, electrolyte, and acid-base metabolism. Continued worsening of renal function is followed by the uremic syndrome, which includes multiple dysfunction of major organ systems in addition to the abnormalities of excretory function described. Finally, ESRD appears, at which time the remaining renal function is unable to sustain normal body function, therefore renal replacement therapy is required at this time (**Luke, 1988**).

Etiology of Chronic Renal Failure

Chronic renal failure may be developed by various number of diseases including, chronic glomerulonephritis, chronic pyelonephritis, nephrosclerosis, diabetic glomerulosclerosis, traumatic loss of kidney tissues, congenital polycystic kidney, or hydronephrosis resulting from obstructive lesions, stones, tumors, strictures, or prostatic enlargement. Collagen diseases as lupus erythematosus, polyarteritis nodosa, anaphylactoid

purpura, and scleroderma, are also contributing in development of chronic renal failure **(Luke, 1988; Guyton, 1991)**.

Replacement Therapy of End Stage Renal Disease

End-stage renal disease requires one of the various forms of renal replacement therapy; chronic hemodialysis, peritoneal dialysis, or kidney transplantation from alive related or cadaveric donor **(Luke, 1988)**.

Dialytic therapy should be started when conservative management fails to maintain the patient in reasonable comfort. Usually dialysis will be required if a creatinine clearance below 5ml/minute, a serum creatinine more than 10mg/dL, blood urea more than 200mg/dL, a serum potassium more than 7mEq/L or serum bicarbonate less than 12mEq/L, **(Gotch and Keen, 1991)**. However, biochemical abnormalities as indicators for starting dialysis are pointers rather than decisive criteria **(Bonomini, 1989)**. Broadly speaking, the development of uremic encephalopathy, neuropathy, pericarditis, and bleeding diathesis are indications to start dialysis immediately. On the other hand, dialysis can be used in non uremic patients with fluid overload **(Weidmann, 1989)**, congestive heart failure **(Agostoni, et al, 1993)**, hyperkalemia, metabolic acidosis, and hypertension uncontrolled by conservative measures **(Zollo, 1991)**.